164 related articles for article (PubMed ID: 7526567)
1. Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.
Saxena M; Di Fabio JL
Vaccine; 1994 Aug; 12(10):879-84. PubMed ID: 7526567
[TBL] [Abstract][Full Text] [Related]
2. Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model.
Jazani NH; Worobec E; Shahabi S; Nejad GB
Can J Microbiol; 2005 Apr; 51(4):319-24. PubMed ID: 15980894
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
4. Salmonella typhi O:9,12 polysaccharide-protein conjugates: characterization and immunoreactivity with pooled and individual normal human sera, sera from patients with paratyphoid A and B and typhoid fever, and animal sera.
Aron L; Di Fabio J; Cabello FC
J Clin Microbiol; 1993 Apr; 31(4):975-8. PubMed ID: 7681853
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
7. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
Rubinstein LJ; García-Ojeda PA; Michon F; Jennings HJ; Stein KE
Infect Immun; 1998 Nov; 66(11):5450-6. PubMed ID: 9784556
[TBL] [Abstract][Full Text] [Related]
8. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine.
Watson DC; Robbins JB; Szu SC
Infect Immun; 1992 Nov; 60(11):4679-86. PubMed ID: 1383154
[TBL] [Abstract][Full Text] [Related]
9. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
10. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
11. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
Beuvery EC; Roy R; Kanhai V; Jennings HJ
Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115
[TBL] [Abstract][Full Text] [Related]
14. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.
Boutonnier A; Villeneuve S; Nato F; Dassy B; Fournier JM
Infect Immun; 2001 May; 69(5):3488-93. PubMed ID: 11292781
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.
Gupta RK; Egan W; Bryla DA; Robbins JB; Szu SC
Infect Immun; 1995 Aug; 63(8):2805-10. PubMed ID: 7542631
[TBL] [Abstract][Full Text] [Related]
17. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
18. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
Jennings HJ; Lugowski C
J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
[TBL] [Abstract][Full Text] [Related]
19. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
